- Home
- DOOO vs GH Comparison
DOOO vs GH Comparison
Compare DOOO & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOOO
- GH
- Stock Information
- Founded
- DOOO 1937
- GH 2011
- Country
- DOOO Canada
- GH United States
- Employees
- DOOO N/A
- GH N/A
- Industry
- DOOO
- GH Medical Specialities
- Sector
- DOOO
- GH Health Care
- Exchange
- DOOO Nasdaq
- GH Nasdaq
- Market Cap
- DOOO 4.8B
- GH 4.9B
- IPO Year
- DOOO N/A
- GH 2018
- Fundamental
- Price
- DOOO $65.79
- GH $68.90
- Analyst Decision
- DOOO Buy
- GH Strong Buy
- Analyst Count
- DOOO 6
- GH 22
- Target Price
- DOOO $72.60
- GH $66.27
- AVG Volume (30 Days)
- DOOO 192.1K
- GH 2.0M
- Earning Date
- DOOO 12-05-2025
- GH 10-29-2025
- Dividend Yield
- DOOO 0.93%
- GH N/A
- EPS Growth
- DOOO N/A
- GH N/A
- EPS
- DOOO N/A
- GH N/A
- Revenue
- DOOO $5,602,586,799.00
- GH $828,849,000.00
- Revenue This Year
- DOOO $6.01
- GH $28.28
- Revenue Next Year
- DOOO $6.23
- GH $23.00
- P/E Ratio
- DOOO N/A
- GH N/A
- Revenue Growth
- DOOO N/A
- GH 28.74
- 52 Week Low
- DOOO $31.78
- GH $20.82
- 52 Week High
- DOOO $68.45
- GH $73.31
- Technical
- Relative Strength Index (RSI)
- DOOO 52.37
- GH 58.54
- Support Level
- DOOO $64.84
- GH $68.33
- Resistance Level
- DOOO $68.18
- GH $73.31
- Average True Range (ATR)
- DOOO 1.92
- GH 2.89
- MACD
- DOOO -0.23
- GH 0.20
- Stochastic Oscillator
- DOOO 42.17
- GH 64.18
About DOOO BRP Inc. (Recreational Products) Common Subordinate Voting Shares
BRP designs, develops, manufactures, distributes, and markets snowmobiles, all-terrain vehicles, and personal watercraft under the Ski-Doo, Sea-Doo, Can-Am, and Lynx brand names. It also builds engines under the Rotax brand (after shuttering the Evinrude outboard engine business in 2020) and offers clothing, parts, and accessories that cater to its core consumers. In 2018, BRP created a marine group, which has largely been divested (Manitou pontoon boats sale is set to close in the third quarter). At the end of fiscal 2025, the company sold its products through a network of more than 2,400 independent dealers and 140 distributors in around 130 countries.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.